Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review ; volume:41 ; number:5 ; day:11 ; month:3 ; year:2024 ; pages:1775-1794 ; date:5.2024
Advances in therapy ; 41, Heft 5 (11.3.2024), 1775-1794, 5.2024

Creator: Allegretti, Jessica R.
Brady, Jessica H.
Wicker, Ann
Latymer, Mark
Wells, Alvin

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12325-024-02818-9

URN: urn:nbn:de:101:1-2407092118531.369879551694

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Allegretti, Jessica R.
Brady, Jessica H.
Wicker, Ann
Latymer, Mark
Wells, Alvin
SpringerLink (Online service)

Other Objects (12)

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

Related objects

Reset password